Matt O'Brien
Stock Analyst at Piper Sandler
(2.39)
# 2,621
Out of 5,090 analysts
195
Total ratings
46.63%
Success rate
-2.19%
Average return
Main Sectors:
Stocks Rated by Matt O'Brien
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TELA TELA Bio | Reiterates: Neutral | $2 → $1.25 | $1.12 | +12.11% | 7 | Nov 14, 2025 | |
| SI Shoulder Innovations | Reiterates: Overweight | $18 | $15.12 | +19.05% | 2 | Nov 12, 2025 | |
| CNMD CONMED | Maintains: Overweight | $68 → $55 | $44.24 | +24.32% | 14 | Nov 6, 2025 | |
| PRCT PROCEPT BioRobotics | Reiterates: Overweight | $55 → $50 | $35.68 | +40.13% | 5 | Nov 5, 2025 | |
| DXCM DexCom | Maintains: Overweight | $100 → $75 | $65.27 | +14.91% | 13 | Oct 31, 2025 | |
| ATEC Alphatec Holdings | Reiterates: Overweight | $20 → $25 | $21.23 | +17.79% | 4 | Oct 31, 2025 | |
| TMDX TransMedics Group | Maintains: Overweight | $145 → $140 | $138.69 | +0.94% | 13 | Oct 30, 2025 | |
| BBNX Beta Bionics | Reiterates: Overweight | $26 → $32 | $30.23 | +5.86% | 2 | Oct 29, 2025 | |
| ITGR Integer Holdings | Maintains: Overweight | $155 → $82 | $70.62 | +16.11% | 3 | Oct 24, 2025 | |
| KIDS OrthoPediatrics | Maintains: Overweight | $30 → $22 | $18.16 | +21.15% | 3 | Oct 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $18 | $14.21 | +26.72% | 1 | Aug 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $30 → $14 | $20.65 | -32.20% | 9 | Aug 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $100 → $80 | $88.74 | -9.85% | 12 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $20 → $12 | $9.39 | +27.80% | 9 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $180 → $165 | $108.85 | +51.58% | 10 | Apr 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $27 | $24.35 | +10.88% | 1 | Mar 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $5.5 → $3.5 | $8.35 | -58.08% | 7 | Mar 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $255 → $140 | $118.86 | +17.79% | 5 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $285 → $310 | $316.45 | -2.04% | 8 | Feb 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $250 → $330 | $294.72 | +11.97% | 13 | Feb 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $40 → $50 | $39.36 | +27.03% | 3 | Feb 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $40 → $16 | $26.47 | -39.55% | 7 | Feb 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $95 → $115 | $97.72 | +17.68% | 3 | Feb 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $9 → $12 | $3.54 | +238.98% | 7 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $380 → $420 | $364.35 | +15.27% | 12 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $85 → $90 | $101.99 | -11.76% | 9 | Aug 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $25 | $19.33 | +29.33% | 1 | Mar 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $3.5 → $3 | $1.30 | +130.77% | 2 | Nov 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $4 → $4.5 | $4.06 | +10.97% | 2 | Aug 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | n/a | $93.16 | - | 2 | Mar 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $15 | $4.71 | +218.47% | 1 | Feb 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $93 → $109 | $77.30 | +40.69% | 1 | Feb 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $25 → $18 | $1.06 | +1,615.09% | 2 | Jan 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $100 → $80 | $18.48 | +332.90% | 1 | Jan 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $12 | $5.62 | +113.52% | 1 | Jun 24, 2020 |
TELA Bio
Nov 14, 2025
Reiterates: Neutral
Price Target: $2 → $1.25
Current: $1.12
Upside: +12.11%
Shoulder Innovations
Nov 12, 2025
Reiterates: Overweight
Price Target: $18
Current: $15.12
Upside: +19.05%
CONMED
Nov 6, 2025
Maintains: Overweight
Price Target: $68 → $55
Current: $44.24
Upside: +24.32%
PROCEPT BioRobotics
Nov 5, 2025
Reiterates: Overweight
Price Target: $55 → $50
Current: $35.68
Upside: +40.13%
DexCom
Oct 31, 2025
Maintains: Overweight
Price Target: $100 → $75
Current: $65.27
Upside: +14.91%
Alphatec Holdings
Oct 31, 2025
Reiterates: Overweight
Price Target: $20 → $25
Current: $21.23
Upside: +17.79%
TransMedics Group
Oct 30, 2025
Maintains: Overweight
Price Target: $145 → $140
Current: $138.69
Upside: +0.94%
Beta Bionics
Oct 29, 2025
Reiterates: Overweight
Price Target: $26 → $32
Current: $30.23
Upside: +5.86%
Integer Holdings
Oct 24, 2025
Maintains: Overweight
Price Target: $155 → $82
Current: $70.62
Upside: +16.11%
OrthoPediatrics
Oct 10, 2025
Maintains: Overweight
Price Target: $30 → $22
Current: $18.16
Upside: +21.15%
Aug 18, 2025
Initiates: Overweight
Price Target: $18
Current: $14.21
Upside: +26.72%
Aug 7, 2025
Downgrades: Neutral
Price Target: $30 → $14
Current: $20.65
Upside: -32.20%
May 9, 2025
Maintains: Overweight
Price Target: $100 → $80
Current: $88.74
Upside: -9.85%
May 9, 2025
Maintains: Overweight
Price Target: $20 → $12
Current: $9.39
Upside: +27.80%
Apr 15, 2025
Maintains: Overweight
Price Target: $180 → $165
Current: $108.85
Upside: +51.58%
Mar 31, 2025
Initiates: Overweight
Price Target: $27
Current: $24.35
Upside: +10.88%
Mar 6, 2025
Maintains: Neutral
Price Target: $5.5 → $3.5
Current: $8.35
Upside: -58.08%
Feb 28, 2025
Downgrades: Neutral
Price Target: $255 → $140
Current: $118.86
Upside: +17.79%
Feb 21, 2025
Maintains: Overweight
Price Target: $285 → $310
Current: $316.45
Upside: -2.04%
Feb 19, 2025
Reiterates: Overweight
Price Target: $250 → $330
Current: $294.72
Upside: +11.97%
Feb 13, 2025
Maintains: Overweight
Price Target: $40 → $50
Current: $39.36
Upside: +27.03%
Feb 12, 2025
Maintains: Neutral
Price Target: $40 → $16
Current: $26.47
Upside: -39.55%
Feb 3, 2025
Maintains: Overweight
Price Target: $95 → $115
Current: $97.72
Upside: +17.68%
Nov 8, 2024
Reiterates: Neutral
Price Target: $9 → $12
Current: $3.54
Upside: +238.98%
Oct 30, 2024
Reiterates: Overweight
Price Target: $380 → $420
Current: $364.35
Upside: +15.27%
Aug 21, 2024
Maintains: Neutral
Price Target: $85 → $90
Current: $101.99
Upside: -11.76%
Mar 28, 2024
Initiates: Overweight
Price Target: $25
Current: $19.33
Upside: +29.33%
Nov 10, 2023
Maintains: Neutral
Price Target: $3.5 → $3
Current: $1.30
Upside: +130.77%
Aug 11, 2023
Maintains: Overweight
Price Target: $4 → $4.5
Current: $4.06
Upside: +10.97%
Mar 10, 2023
Upgrades: Overweight
Price Target: n/a
Current: $93.16
Upside: -
Feb 24, 2023
Initiates: Overweight
Price Target: $15
Current: $4.71
Upside: +218.47%
Feb 11, 2021
Maintains: Overweight
Price Target: $93 → $109
Current: $77.30
Upside: +40.69%
Jan 29, 2021
Downgrades: Neutral
Price Target: $25 → $18
Current: $1.06
Upside: +1,615.09%
Jan 29, 2021
Downgrades: Neutral
Price Target: $100 → $80
Current: $18.48
Upside: +332.90%
Jun 24, 2020
Initiates: Overweight
Price Target: $12
Current: $5.62
Upside: +113.52%